The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment
Abstract
The therapeutic limitations such as insufficient efficacy, drug resistance, metastasis, and undesirable side effects are frequently caused by the long duration monotherapy based on chemotherapeutic drugs. multiple combinational anticancer strategies such as nucleic acids combined with chemotherapeutic agents, chemotherapeutic combinations, chemotherapy and tumor immunotherapy combinations have been embraced, holding great promise to counter these limitations, while still taking including some potential risks. Nowadays, an increasing number of research has manifested the anticancer effects of phytochemicals mediated by modulating cancer cellular events directly as well as the tumor microenvironment. Specifically, these natural compounds exhibited suppression of cancer cell proliferation, apoptosis, migration and invasion of cancer cells, P-glycoprotein inhibition, decreasing vascularization and activation of tumor immunosuppression. Due to the low toxicity and multiple modulation pathways of these phytochemicals, the combination of chemotherapeutic agents with natural compounds acts as a novel approach to cancer therapy to increase the efficiency of cancer treatments as well as reduce the adverse consequences. In order to achieve the maximized combination advantages of small-molecule chemotherapeutic drugs and natural compounds, a variety of functional nano-scaled drug delivery systems, such as liposomes, host-guest supramolecules, supramolecules, dendrimers, micelles and inorganic systems have been developed for dual/multiple drug co-delivery. These co-delivery nanomedicines can improve pharmacokinetic behavior, tumor accumulation capacity, and achieve tumor site-targeting delivery. In that way, the improved antitumor effects through multiple-target therapy and reduced side effects by decreasing dose can be implemented. Here, we present the synergistic anticancer outcomes and the related mechanisms of the combination of phytochemicals with small-molecule anticancer drugs. We also focus on illustrating the design concept, and action mechanisms of nanosystems with co-delivery of drugs to synergistically improve anticancer efficacy. In addition, the challenges and prospects of how these insights can be translated into clinical benefits are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Items 201–224 of 224
Yang, D., Qu, J., Qu, X., Cao, Y., Xu, L., Hou, K., Feng, W., & Liu, Y. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2749-0 · Cited by 29
Hierarchical bioresponsive nanocarriers for codelivery of curcumin and doxorubicin
Lin, J., Ye, Q.-B., Yang, Q., & Wang, G.-H. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.04.023 · Cited by 29
Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells
Qiao, Z., He, M., HE, M., Li, W., Wang, X., WANG, Y., Kuai, Q., LI, C., Ren, S., & Yu, Q. (2016) · Oncology Letters · doi:10.3892/ol.2016.4379 · Cited by 28
Zhao, H., Zhao, D., Jin, H., Li, H., Yang, X., Zhuang, L., & Liu, T. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5426 · Cited by 28
Synergistic Effect of Vitamin C with Cisplatin for Inhibiting Proliferation of Gastric Cancer Cells
Ghavami, G., & Sardari, S. (2019) · Iranian Biomedical Journal · doi:10.29252/ibj.24.2.119 · Cited by 28
Lin, X., Tian, L., Wang, L., Li, W., Xu, Q., & Xiao, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.5614 · Cited by 26
Qiao, Y., Wei, Z., Qin, T., Song, R., Yu, Z., Yuan, Q., Du, J., Zeng, Q., Zong, L., Duan, S., et al. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.03.049 · Cited by 26
Wang, D., Yu, D., Liu, X., Wang, Q., Chen, X., Hu, X., Wang, Q., Jin, C., Wen, L., & Zhang, L. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820962114 · Cited by 25
Yang, Y., Ren, F., Tian, Z., Song, W., Cheng, B., & Feng, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01392 · Cited by 24
Tian, J., Li, M., Liao, J., Li, J., & Tong, X. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/749495 · Cited by 22
Wang, C., Wang, W., Wang, C., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.3599 · Cited by 21
Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells
LI, Z., Wu, C., Wu, J., Ji, M., Shi, L., Jiang, J., Xu, B., & Yuan, J. (2014) · Oncology Letters · doi:10.3892/ol.2014.2368 · Cited by 21
Kutkowska, J., Strządała, L., & Rapak, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103234 · Cited by 21
β‐Asarone Increases Chemosensitivity by Inhibiting Tumor Glycolysis in Gastric Cancer
Tao, H., Ding, X.-L., Wu, J., Liu, S., Sun, W., Nie, M., Pan, X., & Zou, X. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/6981520 · Cited by 21
Özkan, E., & Bakar‐Ates, F. (2020) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202020200548 · Cited by 21
Yan, Y., Guo, Y., Zhang, W., Ma, C., Zhang, Y.-X., Wang, C., & Wang, H.-X. (2014) · PubMed · Cited by 19
Thulasiraman, P., & Johnson, A. B. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3534 · Cited by 19
Synergistic effect of honokiol and 5‐fluorouracil on apoptosis of oral squamous cell carcinoma cells
Ji, N., Jiang, L., Deng, P., Xu, H. Y., Chen, F., Liu, J., Li, J., Liao, G., Zeng, X., Lin, Y., et al. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12481 · Cited by 18
Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells
Liu, X., & Sun, G.-Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6702 · Cited by 18
Lee, M., Shi, C., Hsu, Y.-C., Huang, K.-J., Chen, S., Zhao, P., Chung, H.-C., Huang, Y., & Lee, Y. (2019) · Anticancer Research · doi:10.21873/anticanres.13871 · Cited by 13
Liang, Z., Li, J., & Zhu, B. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s251749 · Cited by 11
Pterostilbene enhances sorafenib’s anticancer effects on gastric adenocarcinoma
Zhao, T., Wang, C., Huo, X., He, M., & Chen, J. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15795 · Cited by 9
Kang, X., Lü, P., Cui, Y., Wang, Y., Zhang, Q., Gong, Y., & Xu, Z. (2015) · PubMed · Cited by 6
(2001) · PubMed
Cited by
Natural Products as Anticancer Agents: Current Status and Future Perspectives
Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., & Zheng, Q. (2022) · Molecules · doi:10.3390/molecules27238367 · Cited by 607
Self-citationLiu, Y., Liu, Y., Sun, X., Wang, Y., Du, C., & Bai, J. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100903 · Cited by 19
Metadata
- Authors
- Gao, Q., Feng, J., Liu, W., Wen, C., Wu, Y., Liao, Q., Zou, L., Sui, X., Xie, T., Zhang, J., & Hu, Y.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 188
- Pages
- 114445
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W4284961560
- Cited by
- 267
- References
- 224
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.